|
**Overview**: Diabetes Type 1 Autoimmune Panel**Introduction**: The Diabetes Type 1 Autoimmune Panel is a diagnostic tool designed to screen for type 1 diabetes autoantibodies using serum samples. In India, type 1 diabetes (T1D) affects ~0.1-0.3 percent of children and young adults, with autoimmune markers (anti-GAD, anti-IA2, anti-insulin, anti-ZnT8, ICA) confirming autoimmune etiology in ~85-95 percent of cases. High morbidity from underdiagnosis in rural/low-SES children, limited pediatric endocrinology access, delayed insulin therapy leading to diabetic ketoacidosis or long-term complications. Per endocrinology practices aligned with ICMR and Indian Society for Pediatric and Adolescent Endocrinology guidelines, the test employs immunoassay for multiple autoantibodies over 1-2 days with high specificity, valuable for differentiating T1D from type 2 or monogenic diabetes. This diagnostic falls under autoimmune screening and targets children/young adults with new-onset diabetes or family history, addressing accurate detection to guide insulin regimen and monitoring. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise classification and reducing acute/late complications. Its serum-based approach ensures reliable autoantibody detection.**Other Names**: Diabetes T1 Pnl.**FDA Status**: FDA approved, CLIA certified for immunology/endocrinology, compliant with 2025 standards.**Historical Milestone**: Autoantibody panel standard; in India, used in pediatric diabetes clinics.**Purpose**: The test screens for 6 parameters including anti-GAD to guide type 1 diabetes assessment, confirm autoimmunity, inform insulin therapy.**Test Parameters**: 1. Anti-GAD, 2. Anti-IA2, 3. Anti-Insulin, 4. Anti-ZnT8, 5. ICA, 6. Total IgA.**Pretest Condition**: No fasting required; patients should report polyuria, weight loss, or ketoacidosis.**Specimen**: 3 mL serum in 1 SST, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 8 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on age of onset, symptoms, family diabetes history, ketoacidosis episodes.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of untreated T1D including ketoacidosis, benefits of early confirmation, and minimal discomfort from venipuncture.**Procedural Considerations**: The test involves sample processing using immunoassay by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols, and store kits according to manufacturer specifications to ensure reliability.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, hemolysis, or IgA deficiency can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Positive autoantibodies confirm autoimmune T1D, necessitating specialist input. Negative may suggest non-autoimmune diabetes.**Specialist Consultation**: Pediatric endocrinologists should be consulted for management.**Additional Supporting Tests**: C-peptide, OGTT for confirmation.**Test Limitations**: Autoantibodies may be negative in some T1D cases; comprehensive approach required.**References**: Indian Journal of Pediatrics 2024, T1D Studies India 2023. |
